Heart Failure 2019 - 6th World Congress on Acute Heart Failure

25 - 28 May 2019, Athens - Greece

Session Details

Poster Session 2: Chronic Heart Failure – Treatment
Sun 26 May 08:30 - 18:00 Other Poster Session Poster Area - Poster Area

Access slides, videos, reports online via ESC Congress 365 Other resources

List of Presentations

Related documents
08:30P980Small tolerated enalapril doses before ARNI administration predicts adverse events during ARNI up-titrationArgyrios NTALIANIS (Athens, Greece)
08:30P981Prescription of sacubitril/valsartan in a real-world populationJoao AGOSTINHO (Lisboa, Portugal)
08:30P982Use of sacubitril-valsartan in heart failure with reduced ejection fraction: real world experienceFernanda Costa FERREIRA (Cascais- Estoril, Portugal)
08:30P983The dangers of non-heart failure hospitalisation for heart failure patients: frequent medication changes without follow upEthel O'DONOGHUE (Dublin, Ireland)
08:30P985Clinical, echocardiographic and cost improvement after the onset with sacubitril-valsartan in mexican patients with heart failure.Veronica Vanesa GOMEZ LEIVA (Ciudad De Mexico, Mexico)
08:30P987The efficacy of nicorandil for patients with ischemic chronic heart failureFlorina BATAR (Sibiu, Romania)
08:30P988Sequential nephron blockade with diuretics improves diastolic dysfunction in patients with resistant hypertensionDavid FOUASSIER (Paris, France)
08:30P989Optimising heart failure treatment following cardiac resynchronisation therapyKasper PRYDS (Aarhus N, Denmark)
08:30P990Trimetazidine management: an extraordinary clinical response in patients with heart failure (TRIMEX-Study)Eduardo Julian Jose CHUQUIURE (Mexico City, Mexico)
08:30P991Careful volume assessment appears to be the critical factor in achieving clinical trial dose of sacubitril/valsartan in the community.Maria FERRE-VALLVERDU (Valencia, Spain)
08:30P992Cardiopulmonary exercise testing as a fundamental tool in the assessment of the functional class in treating sacubitril / valsartan. Results at 3 monthsCristina BELTRAN HERRERA (Madrid, Spain)
08:30P993Safety profile of sacubitril-valsartan in heart failure with reduced ejection fraction with chronic kidney disease, a real life studyAlejandro RECIO MAYORAL (Seville, Spain)
08:30P994Early left ventricular reverse remodeling after sacubitril-valsartan treatment. Subanalysis of SAVE-RLife studyMario GALVAN RUIZ (Las Palmas De G. C., Spain)
08:30P995Impacts of mineralocorticoid receptor antagonists on mortality in heart failure patients with beta-blockersNaoko P KATO (Norrkoping, Sweden)
08:30P996Response rate to sacubitril-valsartan in the community. Is there a clear phenotype?Rebabonye PHARITHI (Dublin 16, Ireland)
08:30P997Treatment of patients with heart failure with reduced ejection fraction (HFrEF) in Germany: differences between cardiologists and primary care physicansUwe ZEYMER (Ludwigshafen, Germany)
08:30P998Effects of sacubitril/valsartan on cardiac performance and exercise capacityMassimo MAPELLI (Milano, Italy)
08:30P999Self-motivation, self-regulation and self-care in patients with heart failure: a sequential mixed-method studyHan Shi Jocelyn CHEW (Hong Kong, Hong Kong)
08:30P1000Benefits of full yogic breathing for patients with chronic heart failureAnna SHEVELYOK (Donetsk, Ukraine)
08:30P1001Analysis of the effectiveness of health education imparted by nursing in an heart failure unitMaria Del Carmen DURAN TORRALBA (Andujar, Spain)
08:30P1002Comparative analysis of the European Heart Failure Self-Care Behavior Scale and the Self-care of Heart Failure Index in hospitalized patients with heart failure.Ekaterina KARTAMYSCHEVA (Volgograd, Russian Federation)
08:30P1003Utility of the implementation of a standardized evaluation program for therapeutic adherence in heart failureMaria Del Carmen DURAN TORRALBA (Andujar, Spain)
08:30P1004A propensity-matched study of moderate to severe obesity and mortality in heart failurePao-Hsien CHU (Taipei, Taiwan, Province of China)
08:30P1006The influence of socio-clinical variables on the level of self-care in heart failure patientsMarta WLEKLIK (Wroclaw, Poland)
08:30P1007Effects of time perspective and executive function on self-care in patients with heart failure: a cross-sectional study Han Shi Jocelyn CHEW (Hong Kong, Hong Kong)
08:30P1008Real world usage and outcomes of all HFrEF patients treated with sacubitril/valsartan in BelgiumTahnee SENTE (Vilvoorde, Belgium)
08:30P1009Sacubitril-valsartan and its effect on ventricular remodelingSusana DEL PRADO DIAZ (Madrid, Spain)
08:30P1010Short and medium-term safety and tolerability of Sacubitril-Valsartan and Empaglifozin joint intakeHerminio MORILLAS CLIMENT (Valencia, Spain)
08:30P1011Angiotensin receptor-neprilysin inhibition improves peak oxygen consumption in reduced heart failure patientsCatia FERREIRA (Coimbra, Portugal)
08:30P1012Sacubitril/Valsartan use in a real world experience: data from a large single-center population of heart failure patients with reduced ejection fractionMassimo MAPELLI (Milano, Italy)
08:30P1015Use of sacubitril-valsartan in elderly patients. Subanalysis of the SAVE-RLife studyMario GALVAN RUIZ (Las Palmas De G. C., Spain)
08:30P1016Allopurinol safety and efficacy in heart failure patients: a systematic reviewMohammad Mostafa ANSARI-RAMANDI (Tehran, Iran (Islamic Republic of))
08:30P1017Initial experience of a nursing consultation in the uptitration of neurohumoral treatment in patientes with heart failure and reduced ejection fractionVanessa ESCOLAR PEREZ (Balmaseda, Spain)
08:30P1018The impact of the use of sacubitril/valsartan on clinical and echocardiographic parameters in heart failure patientsAbdallah ALMAGHRABY (Alexandria, Egypt)
08:30P1019The efficacy of "Get With the Guidelines Heart Failure," a retrospective analysisPerry FISHER (Astoria, United States of America)
08:30P1020Echocardiographic assessment of treating patients with chronic heart failure with mid-range ejection fraction by external counterpulsation Tofig JAHANGIROV (Baku, Azerbaijan)
08:30P1021Early effects of Sacubitril/valsartan on exercise tolerance in patients with heart failure with reduced ejection fraction. Giuseppe VITALE (Palermo, Italy)
08:30P1022In-hospital management of disease modifying drugs in heart failure with reduced ejection fraction - an opportunity to improve?Francisco ADRAGAO (Cascais, Portugal)
08:30P1023Adherence to therapy in patients with chronic heart failure Elena EFREMOVA (Ulyanovsk, Russian Federation)
08:30P1024Hemodynamic and clinical effects of ARNI therapy in patients with advanced heart failure undergoing repeated Levosimendan infusions 
08:30P1026Quality of heart failure treatment treated by residential cardiologists -The HeartFailureBavaria ProjectFabian BISENIUS (Essen, Germany)
08:30P1027To evaluate the safety and tolerability of ARNI initiation in inpatient versus outpatient setting in an Asian population: a real world studyYiliang ZHENG (Singapore, Singapore)
08:30P1028The optimize-heart failure care program in our heart institute in VietnamThi Nam Phuong DO (Ho Chi Minh, Viet Nam)
08:30P1031Inpatient versus outpatient introduction of angiotensin receptor neprilysin inhibitor in chronic heart failure patientsMehdi ALEYAN (Lyon, France)
08:30P1032Management of patients with advanced heart failure and type 2 pulmonary hypertension.Marketa HEGAROVA (Praha 4, Czechia)
08:30P1033Neuroendocrine inhibition in patients with heart failure and severe aortic stenosis undergoing TAVIJesus E PINO MORENO (Atlantis, United States of America)
08:30P1035Levosemindan using in pediatric patients with end-stage heart failure: single center experience.Almira BAIGALKANOVA (Astana, Kazakhstan)
08:30P1036Availability and accessibility to heart failure treatment in latin americaStephania GALINDO (Cali, Colombia)
08:30P1037Decongestion therapy: does it differ from discharge to usual life conditions and among heart failure patients?Francisco ADRAGAO (Cascais, Portugal)
08:30P1038The European Heart Failure self-care behaviour scale: psychometric testing of the Hebrew versionTuvia BEN GAL (Ramat Hasharon, Israel)